Developer docs
API playgroundTry for free, no card

Search company profiles

Cellaviva

Full company profile

uuid0028fuq

Namestring
Cellaviva
Legal namestring
Cellaviva AB
Websiteurl
cellaviva.se
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Cellaviva AB is a Swedish tissue establishment and biobank founded in 2014 by researchers from Karolinska Institutet and headquartered in Huddinge, Sweden. The company operates as a wholly-owned subsidiary of NextCell Pharma AB, a public biotech focused on regenerative medicine and cell therapy. Cellaviva's core offering is the collection, processing, and long-term cryogenic storage of stem cells from umbilical cord blood, umbilical cord tissue, and placenta at birth, using a CE-marked medical device collection kit (the Cellavivabox) and ISO 15189/EFI-accredited laboratory partners. Mesenchymal stem cells from cord tissue are isolated and characterized rather than stored as raw tissue, with sterility and viability testing prior to cryopreservation. Storage is conducted under continuous monitoring in compliance with the EU tissue directive, Swedish biobankslagen, GDPR, and IVO supervision (biobank registration number 932).

The company's business model combines one-time transactional revenue (stem cell collection and genetic tests priced 3,700-8,000 SEK each) with recurring annual cryogenic storage subscriptions, sold direct-to-consumer via its own e-commerce site (www.cellaviva.se) with home-delivered test kits and digital contract signing. Since 2024, Cellaviva has expanded into genetic health testing with the launch of Transplant Match HLA (transplant compatibility), Cellaviva Fertility Insight (55-gene female, 40-gene male, and thrombophilia/NAIT panels), and Celiac Risk & Genetic Analysis, all based on saliva or cheek swab samples analyzed via NGS. A comprehensive whole-genome NIPT is slated for 2026. Through its membership in the FamiCord Group, Europe's largest family stem cell banking network, Cellaviva gains access to 1,500+ partner hospitals and clinics, 15+ laboratories, 1M+ stored samples, and the FamiCord Expanded Access Protocol for cord blood therapy in cerebral palsy and autism. Primary customers are expecting families (stem cell banking), individuals and couples with fertility challenges, families with transplant needs, and individuals seeking celiac or health risk genetic insights.

Short descriptiontext

Cellaviva is a Swedish biobank and DTC genetic health platform offering cord blood/tissue stem cell banking plus NGS-based genetic tests (HLA, fertility, celiac), serving expecting families and consumers across Sweden and the EU.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHuddinge, Sweden
HQ citystring
Huddinge
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
stem cell banking, cord blood storage, genetic health testing, HLA typing, cryogenic biobanking
Product category
Stem Cell Banking & Genetic Health Testing
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Stem Cell Banking Services
TypeSubscription Recurring
Description

One-time collection, processing, analysis, and cryopreservation of stem cells from cord blood, cord tissue, and placenta at birth, with ongoing long-term storage fees. Recurring annual storage fees apply for the storage period selected by the family.

cellaviva.se
2Genetic and Health Testing
TypeOne Time License
Description

One-time fees for genetic tests including Transplant Match HLA (8,000 SEK), Celiac Risk & Genetic Analysis (3,700 SEK), and Fertility Insight panels. These are discrete, per-test transactions with no recurring obligation.

cellaviva.se
3Storage Subscription
TypeSubscription Recurring
Description

Ongoing annual or multi-year cryogenic storage fees for preserved stem cells, billed periodically according to the customer's selected storage plan.

cellaviva.se
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
Pricing details8 tiers
1Celiac Risk & Genetic Analysis
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

3,700 SEK per test. Saliva-based HLA-DQ2/DQ8 genotyping. Results in approximately 2–4 weeks. No gluten exposure required.

cellaviva.se
2Transplant Match HLA Test (Standard)
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

8,000 SEK per test. Includes home cheek swab kit. Results in approximately 4 weeks. Analyzes HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1, HLA-DPB1 at high resolution.

cellaviva.se
3Transplant Match HLA — Priority In-Clinic Sample Collection
ModelUnit PricingBilling cadencePay-as-you-go
Notes

8,000 SEK + 1,495 SEK. Priority in-clinic sample collection at Cellaviva's facility for faster handling and reduced turnaround time. Includes trained staff, controlled medical setting, and same-day laboratory shipment.

cellaviva.se
4Cellaviva Fertilitetsinsikt — Fertility Panel for Couples
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Combined female (55 genes) and male (40 genes + sex chromosomes) fertility panels, plus optional thrombophilia & NAIT panel add-on. Saliva/cheek swab. Results in approximately 2–4 weeks.

cellaviva.se
5Cellaviva Fertilitetsinsikt — Female Fertility Panel (55 genes)
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Genetic analysis of 55 genes linked to female infertility including POI, PCOS, absent ovulation, low ovarian reserve, OHSS, and metabolic/endocrine conditions. Saliva-based cheek swab. Results in approximately 2–4 weeks.

cellaviva.se
6Cellaviva Fertilitetsinsikt — Male Fertility Panel (40 genes + sex chromosomes)
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Genetic analysis of 40 genes plus sex chromosomes linked to male infertility including azoospermia, hormonal disorders (e.g., Kallmann syndrome), and sex chromosome abnormalities. Saliva-based cheek swab. Results in approximately 2–4 weeks.

cellaviva.se
7Cellaviva Fertilitetsinsikt — Thrombophilia & NAIT Panel (22 variants, 17 genes)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

22 genetic variants across 17 genes associated with increased blood clotting risk (thrombofili), recurrent miscarriage, and Neonatal Alloimmune Thrombocytopenia (NAIT). Available as standalone test or add-on to female/male fertility panels.

cellaviva.se
8International Delivery (EU)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Delivery to EU countries outside Sweden carries an additional fee of 5,000 SEK. Import requirements, local regulations, and carrier restrictions may affect delivery feasibility.

cellaviva.se
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

Cellaviva provides family stem cell banking services, collecting, processing, characterizing, and cryopreserving stem cells from umbilical cord blood, cord tissue, and placenta at birth, then storing the samples long-term under continuous monitoring. The company complements this with NGS-based genetic health tests, including high-resolution HLA typing for transplant compatibility, fertility genetic panels, and HLA-DQ2/DQ8 celiac risk genotyping, all delivered through a direct-to-consumer model with at-home sample collection. Operations are conducted in ISO 15189/EFI-accredited laboratories under IVO supervision as a licensed Swedish tissue establishment and registered biobank.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 85,000+ cord blood transplants performed globally; used in >80 malignant and non-malignant conditions
+2 more records
Product overview1 text field

Cellaviva offers a biobanking and genetic testing platform built around stem cell preservation services and health genetic tests. The core offering is the Cellavivabox, a CE-marked medical device collection kit that enables families to preserve stem cells from three sources at birth: umbilical cord blood (hematopoietic stem cells), umbilical cord tissue (mesenchymal stem cells), and placenta tissue. These biological samples are processed, analyzed, and stored long-term in cryogenic facilities. Complementing the stem cell banking service, Cellaviva provides genetic health tests including Transplant Match HLA (for transplant compatibility), Cellaviva Fertility Insight (female/male fertility genetic panels), and Celiac Risk & Genetic Analysis (HLA-based celiac predisposition testing). An upcoming comprehensive NIPT whole genome analysis test is also in development.

Product and service5 records
1Stamcellssparande (Stem Cell Banking)
CategoryStem Cell Banking Service
Description

Core service for collecting, processing, characterizing (with sterility and viability testing), and long-term cryogenic storage of stem cells from umbilical cord blood, umbilical cord tissue, and placenta collected at birth, intended for expecting families seeking biological insurance for potential future medical treatments.

2Cellavivabox (Collection Kit)
CategoryMedical Device / Collection Kit
Description

CE-marked medical device collection kit (compliant with EU MDR 2017/745) containing sterile equipment, transport materials, and instructions used by trained personnel at partner hospitals to collect cord blood and/or cord tissue from the placenta during childbirth for subsequent Cellaviva processing and storage.

3Transplant Match HLA (Transplantationsmatch HLA)
CategoryGenetic Health Test
Description

Genetic test that uses NGS to perform high-resolution six-digit HLA typing (HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1, HLA-DPB1) for adults and families seeking to determine donor-recipient compatibility for stem cell, bone marrow, or organ transplantation; offered via home cheek swab or priority in-clinic collection at Cellaviva's Huddinge facility.

4Cellaviva Fertilitetsinsikt (Fertility Insight)
CategoryGenetic Health Test
Description

Saliva-based genetic test using next-generation sequencing to analyze fertility-related genetic variants in individuals or couples, with a 55-gene female fertility panel, a 40-gene (+ sex chromosomes) male fertility panel, and an optional 22-variant thrombophilia & NAIT add-on; intended for those with unexplained infertility, recurrent miscarriage, or planning assisted reproductive technology.

5Celiakirisk & Genetisk Analys (Celiac Risk & Genetic Analysis)
CategoryGenetic Health Test
Description

Saliva-based genetic test that uses HLA typing to identify HLA-DQ2 and HLA-DQ8 variants associated with celiac disease risk, providing genetic predisposition information without requiring prior gluten exposure or invasive biopsy; intended for adults and children with suspected gluten-related symptoms, family history of celiac disease, or inconclusive standard testing.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Cellaviva is a member of the FamiCord Group, Europe's largest family stem cell banking network. The network comprises 15+ laboratories and storage locations, 1,500+ partner hospitals and clinics, and has stored 1 million+ stem cell samples. Through this network, Cellaviva offers families access to the FamiCord Group Expanded Access Protocol for Cord Blood in Brain Development — a programme for children with cerebral palsy or autism spectrum disorder who have their own cord blood stored — providing access to investigational cord blood therapy outside traditional clinical trials.

2Professor Magdalena Chrościńska-Krawczyk (University Children's Hospital, Lublin)
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Professor Magdalena Chrościńska-Krawczyk, a pediatric neurologist at the University Children's Hospital in Lublin, is a lead clinical partner in the FamiCord Group Expanded Access Programme for cord blood therapy in cerebral palsy and autism. She leads the clinical evaluation and treatment of eligible children within the programme.

cellaviva.se
3Professor Joanne Kurtzberg / Duke University
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Professor Joanne Kurtzberg and her team at Duke University pioneered much of the clinical research into cord blood use for neurological conditions including cerebral palsy and autism. This foundational research underpins the FamiCord Group Expanded Access Programme in which Cellaviva participates, enabling eligible families to access cord blood therapies.

cellaviva.se
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

The FamiCord Group network includes 1,500+ partner hospitals and clinics across Europe that work with Cellaviva member biobanks for stem cell collection at birth. Midwives and obstetric staff at these facilities use the Cellaviva Box to collect cord blood, cord tissue, and placenta samples for processing and storage.

5ISO 15189 / EFI Accredited Laboratory Partners
Strategic tierCoreTypeTechnology or Integration
Description

HLA typing for Transplant Match testing is performed by laboratories accredited according to ISO 15189, accredited by the European Federation for Immunogenetics (EFI), and operating in accordance with GMP guidelines. Fertility and celiac genetic tests are analyzed by accredited laboratory partners using next-generation sequencing (NGS). Results meet international quality and regulatory standards and are recognized by healthcare providers and transplantation centres throughout Europe.

cellaviva.se
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Cellaviva uses multiple logistics partners including DHL, PostNord, Best Transport, and other courier and express delivery providers for the delivery of collection kits and genetic test kits to customers. Partner selection is individualized based on customer location, delivery urgency, product sensitivity, and cost.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

NextCell Pharma AB is Cellaviva's publicly listed parent company, developing stem cell therapies (ProTrans) using MSCs derived from umbilical cord tissue — the same biological source Cellaviva banks. Closely comparable on underlying biology and regulatory environment, and a key channel for translating banked samples into future approved therapies.

TypeBroad incumbent
Description

FamiCord Group is Europe's largest family stem cell banking network and Cellaviva's parent network. Cellaviva operates as a member biobank under FamiCord, sharing the same cord blood/tissue banking model, FamiCord Box collection kits, and the Expanded Access Protocol for cerebral palsy and autism. Most directly comparable on product, model, and infrastructure footprint (15+ labs, 1M+ stored samples).

TypeDirect peer
Description

UK-headquartered cord blood and tissue banking service operating worldwide with home-collection kits and long-term cryogenic storage. Closely comparable on DTC consumer biobank offering, geographic scope (EU + international), and recurring storage revenue model.

4Biovault Family
TypeDirect peer
Description

European private cord blood bank with HTA-licensed storage in the UK, offering cord blood and tissue processing and cryopreservation. Comparable on regulatory-quality positioning, clinical processing protocols, and DTC model aimed at expecting families.

TypeDirect peer
Description

UK-based private stem cell bank offering cord blood and cord tissue collection with multi-year storage plans. Directly comparable DTC consumer biobank model in Europe, competing for cross-border EU families and using a similar cryogenic storage / annual subscription structure.

TypeBroad incumbent
Description

Asia-Pacific-focused publicly listed cord blood banking group with operations across Singapore, Hong Kong, India, Indonesia, Malaysia, and the Philippines. Comparable on consumer biobank model and recurring storage revenue, though geographically focused outside Cellaviva's core EU market.

TypeBroad incumbent
Description

US-based hybrid public-private cord blood bank combining family storage with a significant public banking registry supplying transplants worldwide. Comparable on biological materials, processing standards, and HLA typing services relevant to Cellaviva's Transplant Match offering.

TypeBroad incumbent
Description

US-based publicly listed family cord blood bank and one of the longest-operating consumer biobanks. Comparable on DTC cord blood + cord tissue storage model, multi-year subscription pricing, and accredited laboratory processing — though operating in a different regulatory environment.

TypeEmerging player
Description

US-listed clinical genetic testing company offering reproductive and oncology genetic tests including non-invasive prenatal testing (NIPT) and carrier screening. Comparable on the genetic testing side of Cellaviva's portfolio — particularly its Cellaviva Fertility Insight panels and upcoming comprehensive NIPT — though Natera is the broader clinical/enterprise incumbent Cellaviva would compete against for prenatal genetic share.

TypeBroad incumbent
Description

Established US family cord blood bank (a Revvity subsidiary) offering cord blood and tissue banking with multi-year storage plans. Comparable on consumer brand, premium positioning, recurring storage model, and integration with broader reproductive/genetic health services from its parent.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cellaviva

Stem Cell Banking & Genetic Health Testingcellaviva.se

Cellaviva is a Swedish biobank and DTC genetic health platform offering cord blood/tissue stem cell banking plus NGS-based genetic tests (HLA, fertility, celiac), serving expecting families and consumers across Sweden and the EU.

What Cellaviva does

Cellaviva AB is a Swedish tissue establishment and biobank founded in 2014 by researchers from Karolinska Institutet and headquartered in Huddinge, Sweden. The company operates as a wholly-owned subsidiary of NextCell Pharma AB, a public biotech focused on regenerative medicine and cell therapy. Cellaviva's core offering is the collection, processing, and long-term cryogenic storage of stem cells from umbilical cord blood, umbilical cord tissue, and placenta at birth, using a CE-marked medical device collection kit (the Cellavivabox) and ISO 15189/EFI-accredited laboratory partners. Mesenchymal stem cells from cord tissue are isolated and characterized rather than stored as raw tissue, with sterility and viability testing prior to cryopreservation. Storage is conducted under continuous monitoring in compliance with the EU tissue directive, Swedish biobankslagen, GDPR, and IVO supervision (biobank registration number 932).

The company's business model combines one-time transactional revenue (stem cell collection and genetic tests priced 3,700-8,000 SEK each) with recurring annual cryogenic storage subscriptions, sold direct-to-consumer via its own e-commerce site (www.cellaviva.se) with home-delivered test kits and digital contract signing. Since 2024, Cellaviva has expanded into genetic health testing with the launch of Transplant Match HLA (transplant compatibility), Cellaviva Fertility Insight (55-gene female, 40-gene male, and thrombophilia/NAIT panels), and Celiac Risk & Genetic Analysis, all based on saliva or cheek swab samples analyzed via NGS. A comprehensive whole-genome NIPT is slated for 2026. Through its membership in the FamiCord Group, Europe's largest family stem cell banking network, Cellaviva gains access to 1,500+ partner hospitals and clinics, 15+ laboratories, 1M+ stored samples, and the FamiCord Expanded Access Protocol for cord blood therapy in cerebral palsy and autism. Primary customers are expecting families (stem cell banking), individuals and couples with fertility challenges, families with transplant needs, and individuals seeking celiac or health risk genetic insights.

Cellaviva firmographics

Firmographics
Name
Cellaviva
Legal name
Cellaviva AB
Website
https://cellaviva.se
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Cellaviva is a Swedish biobank and DTC genetic health platform offering cord blood/tissue stem cell banking plus NGS-based genetic tests (HLA, fertility, celiac), serving expecting families and consumers across Sweden and the EU.
Ownership category
akta.pro rank

Where Cellaviva is headquartered

Location

Headquarters

HQ city
Huddinge
HQ country
Sweden
HQ region
Europe

Offices3 records

Markets served

Cellaviva business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Stem Cell Banking Services: One-time collection, processing, analysis, and cryopreservation of stem cells from cord blood, cord tissue, and placenta at birth, with ongoing long-term storage fees. Recurring annual storage fees apply for the storage period selected by the family.
  2. Genetic and Health Testing: One-time fees for genetic tests including Transplant Match HLA (8,000 SEK), Celiac Risk & Genetic Analysis (3,700 SEK), and Fertility Insight panels. These are discrete, per-test transactions with no recurring obligation.
  3. Storage Subscription: Ongoing annual or multi-year cryogenic storage fees for preserved stem cells, billed periodically according to the customer's selected storage plan.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goCeliac Risk & Genetic Analysis
One time/ perpetual licensePay-as-you-goTransplant Match HLA Test (Standard)
Unit PricingPay-as-you-goTransplant Match HLA — Priority In-Clinic Sample Collection
One time/ perpetual licensePay-as-you-goCellaviva Fertilitetsinsikt — Fertility Panel for Couples
One time/ perpetual licensePay-as-you-goCellaviva Fertilitetsinsikt — Female Fertility Panel (55 genes)
One time/ perpetual licensePay-as-you-goCellaviva Fertilitetsinsikt — Male Fertility Panel (40 genes + sex chromosomes)
Unit PricingPay-as-you-goCellaviva Fertilitetsinsikt — Thrombophilia & NAIT Panel (22 variants, 17 genes)
Unit PricingPay-as-you-goInternational Delivery (EU)

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Cellaviva product offering

Product offering

Core offering

Cellaviva provides family stem cell banking services, collecting, processing, characterizing, and cryopreserving stem cells from umbilical cord blood, cord tissue, and placenta at birth, then storing the samples long-term under continuous monitoring. The company complements this with NGS-based genetic health tests, including high-resolution HLA typing for transplant compatibility, fertility genetic panels, and HLA-DQ2/DQ8 celiac risk genotyping, all delivered through a direct-to-consumer model with at-home sample collection. Operations are conducted in ISO 15189/EFI-accredited laboratories under IVO supervision as a licensed Swedish tissue establishment and registered biobank.

Product overview

Cellaviva offers a biobanking and genetic testing platform built around stem cell preservation services and health genetic tests. The core offering is the Cellavivabox, a CE-marked medical device collection kit that enables families to preserve stem cells from three sources at birth: umbilical cord blood (hematopoietic stem cells), umbilical cord tissue (mesenchymal stem cells), and placenta tissue. These biological samples are processed, analyzed, and stored long-term in cryogenic facilities. Complementing the stem cell banking service, Cellaviva provides genetic health tests including Transplant Match HLA (for transplant compatibility), Cellaviva Fertility Insight (female/male fertility genetic panels), and Celiac Risk & Genetic Analysis (HLA-based celiac predisposition testing). An upcoming comprehensive NIPT whole genome analysis test is also in development.

Differentiator

Problem solved

Functional benefit

Products and services

  • Stamcellssparande (Stem Cell Banking) Core service for collecting, processing, characterizing (with sterility and viability testing), and long-term cryogenic storage of stem cells from umbilical cord blood, umbilical cord tissue, and placenta collected at birth, intended for expecting families seeking biological insurance for potential future medical treatments.
  • Cellavivabox (Collection Kit) CE-marked medical device collection kit (compliant with EU MDR 2017/745) containing sterile equipment, transport materials, and instructions used by trained personnel at partner hospitals to collect cord blood and/or cord tissue from the placenta during childbirth for subsequent Cellaviva processing and storage.
  • Transplant Match HLA (Transplantationsmatch HLA) Genetic test that uses NGS to perform high-resolution six-digit HLA typing (HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1, HLA-DPB1) for adults and families seeking to determine donor-recipient compatibility for stem cell, bone marrow, or organ transplantation; offered via home cheek swab or priority in-clinic collection at Cellaviva's Huddinge facility.
  • Cellaviva Fertilitetsinsikt (Fertility Insight) Saliva-based genetic test using next-generation sequencing to analyze fertility-related genetic variants in individuals or couples, with a 55-gene female fertility panel, a 40-gene (+ sex chromosomes) male fertility panel, and an optional 22-variant thrombophilia & NAIT add-on; intended for those with unexplained infertility, recurrent miscarriage, or planning assisted reproductive technology.
  • Celiakirisk & Genetisk Analys (Celiac Risk & Genetic Analysis) Saliva-based genetic test that uses HLA typing to identify HLA-DQ2 and HLA-DQ8 variants associated with celiac disease risk, providing genetic predisposition information without requiring prior gluten exposure or invasive biopsy; intended for adults and children with suspected gluten-related symptoms, family history of celiac disease, or inconclusive standard testing.

Quantifiable outcome

  • 85,000+ cord blood transplants performed globally; used in >80 malignant and non-malignant conditions
  • +2 more outcomes

Companies that use Cellaviva

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Cellaviva technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Cellaviva partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core, strategic and minor.

  • FamiCord GroupcoreStrategic or Co-development PartnerCellaviva is a member of the FamiCord Group, Europe's largest family stem cell banking network. The network comprises 15+ laboratories and storage locations, 1,500+ partner hospitals and clinics, and has stored 1 million+ stem cell samples. Through this network, Cellaviva offers families access to the FamiCord Group Expanded Access Protocol for Cord Blood in Brain Development — a programme for children with cerebral palsy or autism spectrum disorder who have their own cord blood stored — providing access to investigational cord blood therapy outside traditional clinical trials.
  • Professor Magdalena Chrościńska-Krawczyk (University Children's Hospital, Lublin)coreImplementation/ SI/ Consulting PartnerProfessor Magdalena Chrościńska-Krawczyk, a pediatric neurologist at the University Children's Hospital in Lublin, is a lead clinical partner in the FamiCord Group Expanded Access Programme for cord blood therapy in cerebral palsy and autism. She leads the clinical evaluation and treatment of eligible children within the programme.
  • Professor Joanne Kurtzberg / Duke UniversitystrategicStrategic or Co-development PartnerProfessor Joanne Kurtzberg and her team at Duke University pioneered much of the clinical research into cord blood use for neurological conditions including cerebral palsy and autism. This foundational research underpins the FamiCord Group Expanded Access Programme in which Cellaviva participates, enabling eligible families to access cord blood therapies.
  • FamiCord Group Partner Hospitals and ClinicscoreChannel Partner/ Reseller/ DistributorThe FamiCord Group network includes 1,500+ partner hospitals and clinics across Europe that work with Cellaviva member biobanks for stem cell collection at birth. Midwives and obstetric staff at these facilities use the Cellaviva Box to collect cord blood, cord tissue, and placenta samples for processing and storage.
  • ISO 15189 / EFI Accredited Laboratory PartnerscoreTechnology or IntegrationHLA typing for Transplant Match testing is performed by laboratories accredited according to ISO 15189, accredited by the European Federation for Immunogenetics (EFI), and operating in accordance with GMP guidelines. Fertility and celiac genetic tests are analyzed by accredited laboratory partners using next-generation sequencing (NGS). Results meet international quality and regulatory standards and are recognized by healthcare providers and transplantation centres throughout Europe.
  • DHL, PostNord, Best Transport, and Other Logistics PartnersminorChannel Partner/ Reseller/ DistributorCellaviva uses multiple logistics partners including DHL, PostNord, Best Transport, and other courier and express delivery providers for the delivery of collection kits and genetic test kits to customers. Partner selection is individualized based on customer location, delivery urgency, product sensitivity, and cost.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Cellaviva competitors and assessment

Company assessment

Direct peers

  • NextCell Pharma AB: NextCell Pharma AB is Cellaviva's publicly listed parent company, developing stem cell therapies (ProTrans) using MSCs derived from umbilical cord tissue — the same biological source Cellaviva banks. Closely comparable on underlying biology and regulatory environment, and a key channel for translating banked samples into future approved therapies.
  • Smart Cells International: UK-headquartered cord blood and tissue banking service operating worldwide with home-collection kits and long-term cryogenic storage. Closely comparable on DTC consumer biobank offering, geographic scope (EU + international), and recurring storage revenue model.
  • Biovault Family: European private cord blood bank with HTA-licensed storage in the UK, offering cord blood and tissue processing and cryopreservation. Comparable on regulatory-quality positioning, clinical processing protocols, and DTC model aimed at expecting families.
  • Cells4Life: UK-based private stem cell bank offering cord blood and cord tissue collection with multi-year storage plans. Directly comparable DTC consumer biobank model in Europe, competing for cross-border EU families and using a similar cryogenic storage / annual subscription structure.

Broad incumbents

  • FamiCord Group: FamiCord Group is Europe's largest family stem cell banking network and Cellaviva's parent network. Cellaviva operates as a member biobank under FamiCord, sharing the same cord blood/tissue banking model, FamiCord Box collection kits, and the Expanded Access Protocol for cerebral palsy and autism. Most directly comparable on product, model, and infrastructure footprint (15+ labs, 1M+ stored samples).
  • Cordlife Group: Asia-Pacific-focused publicly listed cord blood banking group with operations across Singapore, Hong Kong, India, Indonesia, Malaysia, and the Philippines. Comparable on consumer biobank model and recurring storage revenue, though geographically focused outside Cellaviva's core EU market.
  • StemCyte: US-based hybrid public-private cord blood bank combining family storage with a significant public banking registry supplying transplants worldwide. Comparable on biological materials, processing standards, and HLA typing services relevant to Cellaviva's Transplant Match offering.
  • Cryo-Cell International: US-based publicly listed family cord blood bank and one of the longest-operating consumer biobanks. Comparable on DTC cord blood + cord tissue storage model, multi-year subscription pricing, and accredited laboratory processing — though operating in a different regulatory environment.
  • ViaCord: Established US family cord blood bank (a Revvity subsidiary) offering cord blood and tissue banking with multi-year storage plans. Comparable on consumer brand, premium positioning, recurring storage model, and integration with broader reproductive/genetic health services from its parent.

Emerging players

  • Natera: US-listed clinical genetic testing company offering reproductive and oncology genetic tests including non-invasive prenatal testing (NIPT) and carrier screening. Comparable on the genetic testing side of Cellaviva's portfolio — particularly its Cellaviva Fertility Insight panels and upcoming comprehensive NIPT — though Natera is the broader clinical/enterprise incumbent Cellaviva would compete against for prenatal genetic share.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Cellaviva social profiles

Digital presence

Cellaviva compliance and trust

Trust signal

Compliance6 records

Cellaviva financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cellaviva leadership team

Management profile

Number of profiles

Cellaviva funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cellaviva M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellaviva

What does Cellaviva do?

Cellaviva provides family stem cell banking services, collecting, processing, characterizing, and cryopreserving stem cells from umbilical cord blood, cord tissue, and placenta at birth, then storing the samples long-term under continuous monitoring. The company complements this with NGS-based genetic health tests, including high-resolution HLA typing for transplant compatibility, fertility genetic panels, and HLA-DQ2/DQ8 celiac risk genotyping, all delivered through a direct-to-consumer model with at-home sample collection. Operations are conducted in ISO 15189/EFI-accredited laboratories under IVO supervision as a licensed Swedish tissue establishment and registered biobank.

Is Cellaviva a public or private company?

Cellaviva is a private company. It is classified as corporate owned and is currently operating.

When was Cellaviva founded?

Cellaviva was founded in 2014. It employs 11 to 50 people.

Where is Cellaviva based?

Cellaviva is headquartered in Huddinge, Sweden, in the Europe region.

How does Cellaviva make money?

Three revenue lines are on record. Stem Cell Banking Services are the primary driver. The others are genetic and Health Testing and storage Subscription.

Who are Cellaviva's main competitors?

Direct peers on record are NextCell Pharma AB, Smart Cells International, Biovault Family and Cells4Life. Broad incumbents are FamiCord Group, Cordlife Group, StemCyte, Cryo-Cell International and ViaCord. Natera is listed as an emerging player.

Does Cellaviva have an API?

No public API is recorded for Cellaviva.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals